KR20120022934A - Ｎ-(2,6-디메틸-4-모르폴린-4-일-페닐)-3,3-디메틸-부티르아미드의 안정한 형태 - Google Patents

Ｎ-(2,6-디메틸-4-모르폴린-4-일-페닐)-3,3-디메틸-부티르아미드의 안정한 형태 Download PDF

Info

Publication number
KR20120022934A
KR20120022934A KR1020117026958A KR20117026958A KR20120022934A KR 20120022934 A KR20120022934 A KR 20120022934A KR 1020117026958 A KR1020117026958 A KR 1020117026958A KR 20117026958 A KR20117026958 A KR 20117026958A KR 20120022934 A KR20120022934 A KR 20120022934A
Authority
KR
South Korea
Prior art keywords
dimethyl
phenyl
morpholin
butyramide
disorders
Prior art date
Application number
KR1020117026958A
Other languages
English (en)
Korean (ko)
Inventor
스벤드 트레펜달
카린 릴토르프
데 디에고 헤이디 로페스
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120022934(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20120022934A publication Critical patent/KR20120022934A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020117026958A 2009-05-11 2010-05-11 Ｎ-(2,6-디메틸-4-모르폴린-4-일-페닐)-3,3-디메틸-부티르아미드의 안정한 형태 KR20120022934A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11
DKPA200900597 2009-05-11

Publications (1)

Publication Number Publication Date
KR20120022934A true KR20120022934A (ko) 2012-03-12

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117026958A KR20120022934A (ko) 2009-05-11 2010-05-11 Ｎ-(2,6-디메틸-4-모르폴린-4-일-페닐)-3,3-디메틸-부티르아미드의 안정한 형태

Country Status (23)

Country Link
EP (1) EP2430008A2 (es)
JP (1) JP2012526152A (es)
KR (1) KR20120022934A (es)
CN (1) CN102459208A (es)
AR (1) AR076556A1 (es)
AU (1) AU2010246724B2 (es)
BR (1) BRPI1013930A2 (es)
CA (1) CA2761383A1 (es)
CL (1) CL2011002814A1 (es)
CO (1) CO6460741A2 (es)
CR (1) CR20110590A (es)
DO (1) DOP2011000351A (es)
EA (1) EA201171381A1 (es)
GE (1) GEP20146006B (es)
IL (1) IL216148A0 (es)
MA (1) MA33351B1 (es)
MX (1) MX2011011885A (es)
NZ (1) NZ596738A (es)
SG (1) SG175968A1 (es)
TN (1) TN2011000557A1 (es)
TW (1) TW201041857A (es)
WO (1) WO2010130260A2 (es)
ZA (1) ZA201108112B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
CN101790374A (zh) * 2007-08-01 2010-07-28 H.隆德贝克有限公司 Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途

Also Published As

Publication number Publication date
AR076556A1 (es) 2011-06-22
IL216148A0 (en) 2012-01-31
SG175968A1 (en) 2011-12-29
NZ596738A (en) 2013-04-26
AU2010246724B2 (en) 2013-03-21
AU2010246724A1 (en) 2011-12-08
JP2012526152A (ja) 2012-10-25
CN102459208A (zh) 2012-05-16
CO6460741A2 (es) 2012-06-15
MA33351B1 (fr) 2012-06-01
TW201041857A (en) 2010-12-01
EP2430008A2 (en) 2012-03-21
GEP20146006B (en) 2014-01-10
WO2010130260A2 (en) 2010-11-18
ZA201108112B (en) 2013-01-30
TN2011000557A1 (en) 2013-05-24
WO2010130260A9 (en) 2012-10-18
WO2010130260A3 (en) 2011-06-16
EA201171381A1 (ru) 2012-05-30
CL2011002814A1 (es) 2012-04-13
DOP2011000351A (es) 2012-01-31
MX2011011885A (es) 2011-12-06
CR20110590A (es) 2012-02-22
CA2761383A1 (en) 2010-11-18
BRPI1013930A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
WO2004041276A1 (ja) 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
KR900001511B1 (ko) 카테콜 유도체 및 그것을 함유하는 중추신경계 퇴행성질환의 진행방지 및 치료제
JP5388867B2 (ja) Ａｄｈｄ、メランコリー、治療抵抗性うつ病またはうつ病における残存症状を処置するためのセロトニンおよびノルエピネフリン再取り込み阻害と組み合わせた４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
JPWO2005079845A1 (ja) 片頭痛予防薬
EP0906100B1 (en) Use of 5-ht 1a? receptor antagonists for the treatment of urinary incontinence
ES2436608T3 (es) Composición medicinal para la prevención o el tratamiento de la vejiga hiperactiva asociada a un trastorno nervioso
KR20120022934A (ko) Ｎ-(2,6-디메틸-4-모르폴린-4-일-페닐)-3,3-디메틸-부티르아미드의 안정한 형태
JP6754033B2 (ja) 胃不全麻痺のための５−ｈｔ４受容体作動薬
US11767286B2 (en) Phenylpropionate compound, preparation method for same, and applications thereof
US8901155B2 (en) Method for treating a TRPV1-mediated disease
EP3233825B1 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
KR20090018630A (ko) 신경병증성 통증의 치료를 위한 세로토닌 및 노르에피네프린 재흡수 억제제와 결합된 4-[2-(4-메틸페닐술파닐)-페닐]피페리딘의 결정형
KR102078433B1 (ko) 변비증의 예방 또는 치료약
US20230301947A1 (en) Compound for preventing and treating psychiatric disorders and use thereof
US20120165325A1 (en) Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US9932302B1 (en) N-phenyl and N-benzyl enaminones and methods for using same
KR102656587B1 (ko) 암의 기원 세포의 사멸용 약학적 조성물
OA19696A (en) Stable Forms of N-(2,6-Dimethyl-4Morpholin-4-YL-Phenyl)-3, 3-DimethylButyramide
CA3198258A1 (en) Medicine for alleviating neuropathic pain
WO2017216576A1 (en) Autophagy inducer compounds
WO2016099394A1 (en) Novel selective delta-opioid receptor agonists useful for the treatment of pain, anxiety and depression.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid